Viw Magazine

Times Advertising


.

Zuellig Pharma and Substipharm Biologics partner to expand access to IMOJEV® vaccine for Japanese encephalitis across Asia

  • Written by Viw Magazine

New commercialisation agreement builds on existing partnership with Zuellig Pharma

SINGAPORE - Media OutReach Newswire - 16 January 2024 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced its commercialisation partnership with pharmaceutical company Substipharm Biologics, to expand access of the IMOJEV® Japanese encephalitis vaccine across nine markets in Asia, including Brunei, Cambodia, Hong Kong, Malaysia, Myanmar, Philippines, Singapore, Taiwan and Vietnam.

Read more

LifeStyle

The Overlooked Side of Transformation Stories: Life After Major Body Changes

Surgical Disclaimer: Any surgical or invasive procedure carries risks. Before proceeding, you shou...

Must-Have Features in a Modern 2 Bed Caravan

The 2 bed caravan segment has evolved significantly in recent years, with modern layouts offering ...

How Fat Freezing Melbourne Treatments Help Reduce Stubborn Body Fat

Achieving a well-balanced body shape often requires regular exercise and healthy eating habits. Ho...

Why an NDIS Provider Plays a Vital Role in Supporting People With Disabilities

Access to the right support services can significantly improve the quality of life for people livi...